These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11967142)

  • 1. Leukodepleted blood products: who really needs them?
    Fogt F
    Transfus Med; 2002 Feb; 12(1):79. PubMed ID: 11967142
    [No Abstract]   [Full Text] [Related]  

  • 2. Leukodepleted blood components: definition of a standard.
    Andreu G; Masse M; Royer SD; Tardivel R
    Transfus Sci; 1998 Dec; 19(4):381-3. PubMed ID: 10351163
    [No Abstract]   [Full Text] [Related]  

  • 3. Logistical problems of supplying leucodepleted blood components within the national blood service.
    Tandy N
    Transfus Sci; 1998 Dec; 19(4):373-4. PubMed ID: 10351160
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges in QA of leucodepleted blood component and current standard(s). Challenges in quality assurance of leukoreduced components.
    Dumont LJ
    Transfus Sci; 1998 Dec; 19(4):377-80. PubMed ID: 10351162
    [No Abstract]   [Full Text] [Related]  

  • 5. French evaluation of conditions for the systematic implementation of leucocyte removal in labile blood products (LBP).
    Chamfly V
    Transfus Sci; 1998 Dec; 19(4):333-42. PubMed ID: 10351148
    [No Abstract]   [Full Text] [Related]  

  • 6. International views on universal leucodepletion: the perspective in NBS, England.
    Wallington T
    Transfus Sci; 1998 Dec; 19(4):347-8. PubMed ID: 10351150
    [No Abstract]   [Full Text] [Related]  

  • 7. Quality of leukodepleted blood products.
    Heaton A
    Transfus Sci; 1995 Jun; 16(2):189-92. PubMed ID: 10155739
    [No Abstract]   [Full Text] [Related]  

  • 8. Operational and research approaches to universal leucodepletion in Scotland.
    Prowse C
    Transfus Sci; 1998 Dec; 19(4):367-9. PubMed ID: 10351158
    [No Abstract]   [Full Text] [Related]  

  • 9. Validation approaches selective/universal leucodepletion: the need for standardised validation strategies.
    Seghatchian MJ; Krailadsiri P
    Transfus Sci; 1998 Dec; 19(4):363-5. PubMed ID: 10351157
    [No Abstract]   [Full Text] [Related]  

  • 10. Leukocyte-poor blood products: filtration mechanisms.
    Steneker I
    Vox Sang; 1994; 67 Suppl 3():159-60. PubMed ID: 7975484
    [No Abstract]   [Full Text] [Related]  

  • 11. International views on universal leucodepletion: the perspective in NBS, Ireland.
    Murphy W
    Transfus Sci; 1998 Dec; 19(4):349-50. PubMed ID: 10351151
    [No Abstract]   [Full Text] [Related]  

  • 12. Leukocyte reduction of blood components: public policy and new technology.
    Dzik S; Aubuchon J; Jeffries L; Kleinman S; Manno C; Murphy MF; Popovsky MA; Sayers M; Silberstein LE; Slichter SJ; Vamvakas EC
    Transfus Med Rev; 2000 Jan; 14(1):34-52. PubMed ID: 10669939
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential clinical benefits and cost savings of universal leucocyte-depletion of blood components.
    Murphy MF
    Transfus Sci; 1998 Dec; 19(4):343-6. PubMed ID: 10351149
    [No Abstract]   [Full Text] [Related]  

  • 14. Leukocyte reduction in blood component therapy.
    Lane TA; Anderson KC; Goodnough LT; Kurtz S; Moroff G; Pisciotto PT; Sayers M; Silberstein LE
    Ann Intern Med; 1992 Jul; 117(2):151-62. PubMed ID: 1605430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Why remove leukocytes from labile blood products in 1995?].
    Andreu G; Belhocine R; Klaren J; Fretz C; Lejus C
    Transfus Clin Biol; 1996; 3(1):57-74. PubMed ID: 8640315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Filtering out the confusion about leukocyte-poor blood components.
    Baranowski L
    J Intraven Nurs; 1991; 14(5):298-306. PubMed ID: 1748913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services.
    Toner RW; Pizzi L; Leas B; Ballas SK; Quigley A; Goldfarb NI
    Appl Health Econ Health Policy; 2011; 9(1):29-37. PubMed ID: 21174480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukodepleted blood components.
    Thomson AR
    Anaesth Intensive Care; 1993 Feb; 21(1):39-43. PubMed ID: 8447605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Production and consumption of blood and blood products in Norway. Factors of quality assurance in transfusion medicine].
    Heier HE
    Tidsskr Nor Laegeforen; 1993 Jan; 113(1):18-22. PubMed ID: 8424244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance and indications for leukocyte-free blood products].
    Jullien AM
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):211-3. PubMed ID: 8337129
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.